Literature DB >> 21080533

Psychiatric disorders: Ketamine modifies mood through mTOR.

Leonie Welberg.   

Abstract

Entities:  

Year:  2010        PMID： 21080533     DOI： 10.1038/nrn2916

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN： 1471-003X            Impact factor:   34.870


× No keyword cloud information.
  5 in total

1.  Remote Limb Ischemic Preconditioning: A Neuroprotective Technique in Rodents.

Authors:  Alice Brandli
Journal:  J Vis Exp       Date:  2015-06-02       Impact factor: 1.355

2.  Effects of Chronic D-Serine Elevation on Animal Models of Depression and Anxiety-Related Behavior.

Authors:  David-Marian Otte; Maria Luisa Barcena de Arellano; Andras Bilkei-Gorzo; Onder Albayram; Sophie Imbeault; Haang Jeung; Judith Alferink; Andreas Zimmer
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

3.  Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.

Authors:  Mitchell J Bartlett; Andrew J Flores; Tony Ye; Saskia I Smidt; Hannah K Dollish; Jennifer A Stancati; Drew C Farrell; Kate L Parent; Kristian P Doyle; David G Besselsen; Michael L Heien; Stephen L Cowen; Kathy Steece-Collier; Scott J Sherman; Torsten Falk
Journal:  Exp Neurol       Date:  2020-07-25       Impact factor: 5.330

4.  mTORC1 Signaling Pathway Mediates Chronic Stress-Induced Synapse Loss in the Hippocampus.

Authors:  Yu-Fei Luo; Xiao-Xia Ye; Ying-Zhao Fang; Meng-Die Li; Zhi-Xuan Xia; Jian-Min Liu; Xiao-Shan Lin; Zhen Huang; Xiao-Qian Zhu; Jun-Jie Huang; Dong-Lin Tan; Yu-Fei Zhang; Hai-Ping Liu; Jun Zhou; Zu-Cheng Shen
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

Review 5.  Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments.

Authors:  Maria Jimena Salcedo-Arellano; Ana Maria Cabal-Herrera; Ruchi Harendra Punatar; Courtney Jessica Clark; Christopher Allen Romney; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2020-11-19       Impact factor: 7.620
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.